Table 3. Methicillin-resistant Staphylococcus aureus bloodstream infections data, Canada, 2017–2021.

MRSA BSI data	Year
	2017		2018		2019		2020		2021
Number of infections and incidence rates
Number of MRSA bloodstream infections	606		767		888		873		855
Rate per 1,000 patient admissions	0.61		0.78		0.85		0.86		0.84
Rate per 10,000 patient days	0.84		1.05		1.14		1.16		1.13
Number of reporting hospitals	65		62		69		81		78
All-cause mortality ratea
Number of deaths	99		144		144		152		159
All-cause mortality rate per 100 cases	16.4		18.8		16.2		17.4		18.6
Antimicrobial resistanceb	n	%	n	%	n	%	n	%	n	%
Erythromycin	455	80.7	527	75.6	602	75.6	501	72.2	440	68.1
Ciprofloxacin	432	76.6	503	72.2	560	70.4	454	65.4	414	64.1
Clindamycin	239	42.4	287	41.2	297	37.3	229	33.0	185	28.6
Tetracycline	35	6.2	49	7.0	62	7.8	46	6.6	51	7.9
Trimethoprim/sulfamethoxazole	8	1.4	13	1.9	15	1.9	16	2.3	27	4.2
Rifampin	9	1.6	6	0.9	7	0.9	6	0.9	8	1.2
Tigecycline	0	0	0	0	0	0	1	0.1	2	0.3
Daptomycin	5	0.9	0	0	3	0.4	5	0.7	5	0.8
Total number of isolates testedc,d	564	N/A	697	N/A	796	N/A	694	N/A	646	N/A

Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; MRSA BSI, methicillin-resistant Staphylococcus aureus bloodstream infection; N/A, not applicable

^a Based on the number of cases with associated 30-day outcome data

^b All MRSA isolates from 2017 to 2021 submitted to National Microbiology Laboratory were susceptible to linezolid and vancomycin

^c In some years, the number of isolates tested for resistance varied by antibiotic

^d Total number reflects the number of isolates tested for each of the antibiotics listed above